First described in 1993, the small regulatory molecules called microRNA or miRNA, have become emerging biomarkers for research in all fields of medical and biological sciences. This new miRNA regulatory domain empowers translational R&D, identifies novel disease biomarkers in biofluids and tissues and develops non-invasive screening and diagnostic tests.
miREIA is a novel, immunoassay-based method of miRNA quantification which involves hybridisation of miRNA isolated from a patient sample to complementary biotinylated DNA oligonucleotide probe. The DNA/RNA hybrids are then captured by a microtiter plate-immobilized monoclonal antibody specific to perfectly matched DNA/miRNA hybrids. The next steps in the assay procedure follow standard ELISA protocols and the assay can be run on common immunoassay equipment. The method is compatible with standard clinical workflow, does not require amplification steps and results are obtained in less than three hours, including miRNA profiling.
BioVendor have a range of miREIA kits available for various research applications. For additional information please contact us directly.